Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts

Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice

(2013) Toshio Nishikawa et al.   CANCER BIOLOGY & THERAPY

Differentiating mTOR inhibitors in renal cell carcinoma

(2013) Sumanta K. Pal et al.   CANCER TREATMENT REVIEWS

mTOR inhibitors in advanced renal cell carcinomas: From biology to clinical practice

(2013) Philippe Barthélémy et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

(2013) Xiaosong Chen et al.   MOLECULAR CANCER RESEARCH

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers

(2013) M. Pourdehnad et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models

(2012) Yesim Gökmen-Polar et al.   BREAST CANCER RESEARCH AND TREATMENT

A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma

(2012) Z. Mihaly et al.   CURRENT CANCER DRUG TARGETS

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

(2012) M R Janes et al.   LEUKEMIA

Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells

(2012) P. B. Makhov et al.   MOLECULAR CANCER THERAPEUTICS

The translational landscape of mTOR signalling steers cancer initiation and metastasis

(2012) Andrew C. Hsieh et al.   NATURE

ATP-Competitive Inhibitors of mTOR: An Update

(2011) S. Schenone et al.   CURRENT MEDICINAL CHEMISTRY

Meta-analysis of Clear Cell Renal Cell Carcinoma Gene Expression Defines a Variant Subgroup and Identifies Gender Influences on Tumor Biology

(2011) A. Rose Brannon et al.   EUROPEAN UROLOGY

mTOR Inhibitors in Advanced Renal Cell Carcinoma

(2011) Martin H. Voss et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Tissue Slice Grafts

(2010) Hongjuan Zhao et al.   AMERICAN JOURNAL OF PATHOLOGY

Genetic heterogeneity and chromatin modifiers in renal clear cell carcinoma

(2010) Peter Staller   Future Oncology

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

(2010) C A Sparks et al.   ONCOGENE

mTOR and cancer: many loops in one pathway

(2009) Alejo Efeyan et al.   CURRENT OPINION IN CELL BIOLOGY

Resistance to targeted therapy in renal-cell carcinoma

(2009) Brian I Rini et al.   LANCET ONCOLOGY

HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma

(2008) John D. Gordan et al.   CANCER CELL

Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells

(2008) Hongjuan Zhao et al.   DIFFERENTIATION

Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2

(2008) Alfredo Toschi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY